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SCHLAP1 is a long noncoding RNA that is reported to func-
tion by depleting the SWI/SNF complex from the genome. 
We investigated the hypothesis that SCHLAP1 affects only 
specific compositions of SWI/SNF. Using several assays, 
we found that SWI/SNF is not depleted from the genome by 
SCHLAP1 and that SWI/SNF is associated with many coding 
and noncoding RNAs, suggesting that SCHLAP1 may function 
in a SWI/SNF-independent manner.
The long noncoding RNA (lncRNA) second chromosome locus 
associated with prostate cancer 1 (SCHLAP1) is a promising bio-
marker for metastatic prostate cancer1,2. SCHLAP1 is proposed to 
function by antagonizing the SWI/SNF complex through direct 
interaction, leading to complete disruption of SWI/SNF genomic 
occupancy1. Evidence for this mechanism comes from the reported 
loss of SMARCB1 occupancy measured by chromatin immunopre-
cipitation followed by sequencing (ChIP–seq)1. SWI/SNF is a large 
multi-subunit chromatin remodeling complex that can be combina-
torially assembled to yield hundreds to thousands of biochemically 
unique complexes3–5. We investigated the alternative hypothesis that 
distinct forms of SWI/SNF are affected by SCHLAP1 expression. 
However, using a varriety of biochemical and genomics assays, we 
demonstrate that SWI/SNF occupancy is unaffected by SCHLAP1 
expression, in contrast to results reported previously1. We show that 
SWI/SNF binds coding and noncoding RNA, raising the possibility 
that SCHLAP1 function is SWI/SNF-independent.
Consistent with the report by Prensner et al.1, we observed an 
interaction between SMARCB1 and SCHLAP1 (Fig. 1a). We next 
generated SCHLAP1-overexpressing benign prostate epithelial cells 
(RWPE1;SCHLAP1 cells) or control cells (RWPE1;LACZ cells)1 
(SCHLAP1 gift of A. Chinnaiyan). This model is the same as 
that originally used to suggest global depletion of SMARCB1 by 
SCHLAP1 (ref. 1). We then confirmed the phenotype of the cells 
with respect to SWI/SNF expression and growth (Fig. 1b and 
Supplementary Figs. 1,2). In addition, we confirmed the key result 
that SCHLAP1 increased cell invasion (Fig. 1c).
To investigate which SWI/SNF subunits were depleted from chro-
matin upon SCHLAP1 expression, we fractionated RWPE1;LACZ 
and RWPE1;SCHLAP1 cells based on subcellular localization or salt 
extraction. Surprisingly, all SWI/SNF subunits assayed remained 
strongly enriched in the chromatin or high salt fractions (Fig. 1d 
and Supplementary Figs. 3–5). Consistent with these biochemical 
experiments, we found that SMARCA4 and SMARCB1 localization 
was not affected in RWPE1;SCHLAP1 cells by immunofluorescence 
(Supplementary Fig. 3b). Immunoprecipitation of SMARCA4 or 
SMARCB1 demonstrated that the SWI/SNF complex remains intact 
in the presence of SCHLAP1 (Supplementary Figs. 3c,6). Finally, we 
used a malignant rhabdoid tumor cell line with inducible SMARCB1 
that, when expressed, causes growth arrest (gift of B. Weissman)6. 
We reasoned that, if SCHLAP1 disrupted SMARCB1 chromatin 
occupancy, then overexpression of SCHLAP1 should allow G401 
cells to proliferate following induction of SMARCB1. However, 
SMARCB1 induction led to growth arrest in a dose-dependent man-
ner (Fig. 1e and Supplementary Figs. 7,8). Together, these results 
demonstrate that SCHLAP1 does not induce changes to SWI/SNF 
composition or its association with chromatin.
We next performed ChIP–seq for three SWI/SNF subunits 
(SMARCB1, SMARCA2, and SMARCA4) in RWPE1;SCHLAP1 
cells. In contrast to a previous report1, we identify robust binding 
for all three subunits in RWPE1 cells expressing SCHLAP1 (Fig. 1f). 
In RWPE1;SCHLAP1 cells, we identified 6,490, 22,185, and 51,505 
peaks for SMARCB1, SMARCA2, and SMARCA4, respectively 
(Supplementary Table 1). This large number of peaks is in con-
trast to the previous report1, which identified approximately 6,500 
SMARCB1 peaks in RWPE1;LACZ cells and close to no peaks in 
the SCHLAP1-expressing cells. The numbers of peaks are consis-
tent with previous work from our laboratory, which showed 30,000–
45,000 SMARCA4 peaks4. In addition, we and others have reported 
a large number of SWI/SNF peaks for a variety of subunits3,4,7,8. 
The majority of SMARCA2 peaks overlapped a SMARCA4 peak 
(Supplementary Fig. 9a), and SWI/SNF peaks were predominantly 
located at promoters (45–75%; Supplementary Fig. 9b)4. SWI/SNF 
binding was most prominent at highly expressed genes, with little to 
no occupancy at non-expressed genes (Fig. 1g; expression data from 
GSE98898 (ref. 9)). These results demonstrate that SCHLAP1 does 
not function by disrupting SWI/SNF occupancy genome-wide, and 
raises the question of how SCHLAP1 functions to promote cell 
invasion and progression to metastatic disease.
To investigate whether SCHLAP1 expression induces chromatin 
changes, we performed assay for transposase-accessible chromatin 
with high-throughput sequencing (ATAC-seq) on RWPE1;LACZ 
and RWPE1;SCHLAP1 cells10. We identified 273 and 3,167 sites 
that open and close, respectively (Supplementary Table 2 and 
Supplementary Fig. 10). The sites that open were more likely to 
be located distally or in introns of genes (Supplementary Fig. 10). 
Sites that open upon SCHLAP1 expression were enriched for dis-
tinct motifs compared to those that close (Supplementary Fig. 11 
and Supplementary Tables 3, 4). Open sites were enriched in motifs 
for TEAD and AP1 transcription factors, which are known to have 
a role in defining oncogenic enhancers (Supplementary Fig. 11 and 
Supplementary Tables 3, 4)11. To test whether these sites became 
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although the level of enrichment was not markedly different between 
the proteins. Among the enriched transcripts was NEAT1, which 
is a known interacting partner of both SWI/SNF13 and SFPQ19–21. 
In addition, we identified high levels of SMARCA4 associ-
ated with MALAT1, whereas SFPQ was not enriched (Fig. 2a,b). 
A recent report showed a functional interaction between 
SMARCA4, HDAC9, and MALAT1, further supporting the speci-
ficity of our result17. Given the widespread binding of SMARCA4 
on many RNAs, and the modest enrichment of SCHLAP1 relative 
to bona fide SWI/SNF interactions such as MALAT1, we interpret 
these data as evidence that the SCHLAP1–SWI/SNF interaction is 
the result of a widespread nonspecific interaction between SWI/
SNF and transcribing RNA. This may be functional as RNA has 
been shown to inhibit activity of SWI/SNF and PRC2 (refs 16,22).
Together, these results demonstrate that the interaction between 
SWI/SNF and SCHLAP1 does not lead to a global depletion of SWI/SNF 
from the genome as reported previously1. We confirm that 
SCHLAP1 induces RWPE1 cells to become more invasive, and our 
results suggest that this phenotype may be driven by a SWI/SNF-
independent mechanism.
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Fig. 1 | SCHLAP1 does not evict SWI/SNF from chromatin. a, Native RIP for SMARCB1. *P =  0.02 (two-sided t-test) for SCHLAP1 versus U1 primer  
sets for SMARCB1 immunoprecipitation. n =  3 independent experiments. Error bars represent the mean, and whiskers represent the standard deviation.  
b, SCHLAP1 expression in RWPE1;LACZ and RWPE1;SCHLAP1 cells relative to GAPDH. n =  3 independent cell lines. Error bars represent mean and  
standard deviation. ND, not detected. c, Invasion assay of RWPE1;LACZ and RWPE1;SCHLAP1 cells using fluorescent intensity (Licor). Representative of 
n =  3 independent invasion assays run on one cell line, P =  0.007 (two-sided t-test). Error bars represent mean and standard deviation. Scales bars,  
500 uM. d, Chromatin fractionation showing SWI/SNF subunit presence in cytoplasm (Cy), nuclear (N), or chromatin (Ch) fractions from RWPE1;LACZ 
and RWPE1;SCHLAP1 cells. Representative images from two independent experiments. e, Quantitation of G401 growth inhibition. n =  4, two independent 
cell lines plated in duplicate, error bars equal mean ±  standard deviation. f, Example browser images for SMARCA4, SMARCA2, and SMARCB1 from 
RWPE1;SCHLAP1 cell ChIP–seq experiments. Aggregate data from two independent ChIP–seq experiments are shown. g, Occupancy for SMARCA4, 
SMARCA2, and SMARCB1, centered on all transcription start sites (GENCODE), aligned by expression in RWPE1 cells. n =  57,662.
activated enhancers, we performed ChIP–seq for H3K4me1, 
H3K4me3, and H3K27ac in RWPE1;LACZ and RWPE1;SCHLAP1 
cells (Supplementary Fig. 10b), but we did not find differences in 
any histone modifications. In addition, SMARCA2, SMARCA4, and 
SMARCB1 remained highly enriched on sites that decrease chroma-
tin openness (Supplementary Fig. 10d). Gene ontology analysis of 
the open sites identified pathways involved in responses to nuclear 
factor-κ B (NF-κ B) signaling, epithelial to mesenchymal transitions, 
and nucleotide metabolism (Supplementary Fig. 11b), whereas 
closed sites were enriched for pathways involved in cell adhe-
sion and signal transduction (Supplementary Fig. 11b). Although 
we noted changes in gene expression associated with ATAC-seq 
changes, we did not detect a significant association with the direc-
tion of altered chromatin openness (Supplementary Fig. 12)1. These 
data suggest that SCHLAP1 could modestly influence chromatin, 
but is not sufficient to induce histone modification changes.
Recent evidence suggests that chromatin regulators display 
widespread interactions with RNA12–17. Therefore, we investigated 
whether SWI/SNF interacts with other lncRNA using crosslinked 
RNA immunoprecipitation and sequencing (RIP-seq) for SMARCA4 
and a general splicing factor (SFPQ) as a control (Fig. 2a,b)18.  
Consistent with previous observations of chromatin regulators, 
we saw widespread enrichment of SMARCA4 on most expressed 
transcripts relative to an immunoglobulin-G (IgG) control 
(Supplementary Tables 5,6)18. Hendrickson et al.18 used the same 
formaldehyde RIP-seq (fRIP-seq) to demonstrate that chromatin reg-
ulators could display either exonic or intronic enrichment. The pat-
tern of SWI/SNF enrichment seemed to be uniform throughout the 
transcript, suggesting that SMARCA4 associates frequently with pri-
mary transcripts (Fig. 2c–f). In contrast, SFPQ was mostly enriched 
at exons and showed high levels of enrichment at the 3′ UTR of many 
transcripts. We observed SMARCA4 and SFPQ signal at SCHLAP1, 
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Fig. 2 | SMARCA4 binds many RNAs. a, Example loci associated with SMARCA4 or SFPQ in 22Rv1 and LNCaP cells. Reads mapping to the forward (+ )  
and reverse (–) strand for each locus are shown. Within cell lines and on the same strand, scales are equal. RIP-seq was performed two times for each 
antibody in each cell line. Arrow in NEAT1 panel denotes a smaller transcript within the longer NEAT1 transcript. b, Quantitation of signal at each of the 
genes in a for each antibody and each cell line. c, Enrichment of reads mapping to exons compared to introns for each immunoprecipitate. *P <  2.2 ×  10−16, 
Wilcoxon test. Boxplots show the first, second, and third quartile, and whiskers extend to 1.5 times the interquartile range. d, Enrichment of reads mapping 
to primary compared to processed transcripts. *P <  2.2 ×  10−16 for both tests, two-sided wilcoxon test. Boxplots show the first, second, and third quartile, 
and whiskers extend to 1.5 times the interquartile range. e, Log2 fold change relative to input is plotted against the average expression of a transcript for 
both the primary and processed transcripts for the three antibodies tested. Red dots indicate genes with a log2 fold change of greater than 1 and an average 
log2 fold change of greater than 0. f, Number of transcripts assigned to the red points in e.
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Methods
Cell culture. RWPE1 cells were purchased from the American Type Culture 
Collection (ATCC) (CRL-11609, lot 61840713) and grown in Keratinocyte Serum 
Free Medium (Life Technologies) supplemented with penicillin and streptomycin. 
Cells were short-tandem repeat (STR) profiled by ATCC before purchase, and all 
experiments were performed on low-passage cells (< 10 passages). Lenti6-LACZ 
was generated by removing SCHLAP1 from the plasmid below and cloning LACZ 
from pLentipuro-LACZ into pLenti6 from which SCHLAP1 was removed by 
EcoRI-BamHI digest. Lenti6-SCHLAP1 was a gift of A. Chinnayian1. Lentiviral 
particles were produced using psPAX2 and pMD2.G to package plasmids in 
293 T cells. RWPE1;LACZ and RWPE1;SCHLAP1 cells were then generated by 
transduction with lentivirus and selecting with 2.5 μ g ml−1 blasticidin for 1 week. 
22RV1 and LNCaP cells were purchased from ATCC (CRL-2505, lot 60437301; 
CRL-1740, lot 62129998) and grown in RPMI 1640 with 10% fetal bovine serum 
FBS solution supplemented with penicillin and streptomycin. Cells were STR 
profiled by ATCC prior to purchase and were used at early passages (< 10 passages). 
All cells were tested for (and found to be free of) mycoplasma contamination.
Antibodies. SMARCA2 (Cell Signaling 11966), lot 2; SMARCA4 (Abcam 
ab110641), GR150844-42; SMARCB1 (Abcam ab192864), GR315927-2; BAF53A 
(Abcam ab3882), GR95633-1; BAF60A (BD Biosciences 611728), 5199785; BAF155 
(Cell Signaling D7F8S), lot 2; BAF180 (Bethyl A301-591A), lot 1; SFPQ (Genetex 
GTX114209), 40828; NCL (Bethyl A300-711A), lot 1; ARID1A (Abcam ab182560), 
GR3186289-2; ARID1B (Abcam ab57461), GR308911-3; ARID2 (ThermoFisher 
PA5-35857), SF24034426; H3K4me3 (Abcam ab8580); H3K4me1 (Active Motif 
39635), 16611004; H3K27ac (Active Motif 39133), 20017049; H3 (epicypher 13-
0001), gift of B. Strahl, available from Epicypher.
Invasion assay. Invasion was assessed using a Corning BioCoat Matrigel Invasion 
Assay with an 8-µ m pore size. Cells were seeded into Boyden chambers at 100,000 
cells per well in 100 µ l of normal growth medium. The lower chamber was filled 
with either normal growth medium supplemented with 10% FBS or PBS solution 
as a negative control. Cells were allowed to invade for 40.25 h, after which the top 
chamber was swabbed to remove non-invading cells. Invading cells were fixed and 
stained with crystal violet. Membranes were imaged using a Zeiss Axio Imager for 
representative images or scanned using a Licor fluorescent imager for quantitation. 
Results are reported as the average of three biological replicates. For each replicate, 
crystal violet fluorescence was measured and background fluorescence was 
subtracted. Background fluorescence of the membranes was obtained from a 
negative control.
RNA immunoprecipitation. RIP experiments were performed using a modified 
version of a protocol from Hendrickson et al.18.
Fixation. 22Rv1 and LNCaP cells were fixed in 0.3% methanol-free formaldehyde 
for 30 min at 4 °C. Formaldehyde was quenched with 125 mM glycine for 5 min 
at 20–25 °C. Plates were washed three times in PBS at 20–25 °C, and cells were 
scraped in 1 mM PMSF (phenylmethyl sulfonyl fluoride) in PBS. Cells were snap 
frozen in liquid nitrogen and stored at − 80 °C.
Fragmentation and immunoprecipitation. Cells were resuspended in 0.5 ml 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 8,  
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 5 mM EDTA, 150 mM 
KCl) plus 0.5 mM DTT with 1× protease inhibitors (Sigma) and 2.5 μ l RNAsin,  
and incubated on ice for 10 min prior to lysing using a Bioruptor (Diagenode)  
for two cycles of 30 s on and 1 min off, followed by centrifugation at 4 °C for 10 min 
at maximum speed. Protein A magnetic beads (Biorad) were pre-conjugated  
with antibody for 2 h at 4 °C. Cells were then incubated overnight at 4 °C with 
antibody-conjugated beads. Beads were washed consecutively with fRIP buffer 
(25 mM Trix-HCl pH 7.5, 5 mM EDTA, 0.5% Ipegal CA-630, 150 mM KCl),  
three times in ChIP buffer (50 mM Tris-HCl pH 7.5, 140 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS),  
1× in high salt buffer (ChIP buffer, but with 500 mM NaCl) and 1× in fRIP buffer. 
All washes were performed for 5 min at 4 °C. After the final wash, beads were 
resuspended in 56 μ l water and 33 μ l of 3× reverse crosslinking buffer (3× PBS, 
6% N-lauroyl sarcosine, 30 mM EDTA) supplemented with 5 mM DTT. We then 
added 20 μ l proteinase K and 1 μ l RNAsin and incubated 1 h at 42 °C, 1 h at 55 °C, 
and 30 min at 65 °C. Following elution and crosslink reversal, Trizol was used to 
extract RNA. Finally, RNA in the aqueous phase was supplemented with 1 volume 
of ethanol and purified using a Zymo-spin IC column, including the on-column 
DNase digestion, as per the manufacturer’s instruction. RNA was eluted in  
15 μ l double distilled water (ddH20) and used to prepare RNA-seq libraries or  
to synthesize cDNA for quantitative PCR. RNA-seq libraries were prepared by 
using equal volumes of immunoprecipitates and included 1 μ l of 1:250 μ l dilution  
of ERCC spike-in mix 1 (Life Technologies). Input libraries were prepared from  
the same amount of RNA as the immunoprecipitate with the most RNA,  
and spike-ins were added as above. Libraries were then prepared using the  
Kapa Ribo-zero kit following the manufacturer’s instructions, pooled, and 
sequenced using single-end 75-bp reads on an Illumina Nextseq 500.
RIP-seq analysis. Reads were aligned, using STAR, to hg38 with GENCODE 
version 27 (v27) annotations that included ERCC spike-ins and using --quantMode 
GeneCounts. In parallel, an alignment-free quantitation method (Salmon version 0.8)  
was used to quantitate GENCODE v27 transcripts containing ERCC spike-ins and 
an extra transcript for each gene that contained the whole genomic DNA locus to 
represent an unspliced transcript. Browser tracks were generated by converting BAM 
files to bigWig files using Deeptools (version 2.5.2) and scaling tracks relative to the 
75th percentile of the ERCC spike-ins. Enrichment of the immunoprecipitate relative 
to IgG was calculated using DESeq2 (v1.18.1) with sizeFactors generated from only 
the ERCC spike-in data. For visualization relative to input, normalized count values 
were used, and log2[RIP/input] was calculated for each gene. RIP-seq data are available 
under GEO accession GSE114393.
Chromatin fractionation. Chromatin fractionation was performed as described 
previously23. Approximately 1 × 107 cells were washed and resuspended in 200 μ 
l Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 
10% glycerol, 1 mM DTT, supplemented with 1× protease inhibitors and 1 mM 
PMSF). Triton X-100 was then added to 0.1% final concentration, and cells were 
incubated for 8 min on ice. Cells were centrifuged at 1,300 g for 5 min at 4 °C. The 
supernatant was saved as the cytosolic fraction and the pellet (nuclei) was washed 
once with Buffer A. Cells were lysed for 30 min on ice in 100 μ l Buffer B (3 mM 
EDTA, 0.2 mM EGTA, 1 mM DTT) supplemented with 1× protease inhibitors
and 1 mM PMSF, and centrifuged at 1,700 g for 5 min at 4 °C. The supernatant was 
saved as the nucleoplasmic fraction, and the insoluble material was resuspended 
in 1× Laemmli buffer, and sonicated twice for 30 s on high power (Bioruptor). All 
lysates were boiled for 10 min in 1× Laemmli buffer with 0.1 M DTT and used in 
western blot analysis.
Salt extraction of nuclei. Salt extraction of chromatin was performed as described 
previously24. Cells were collected from plates prior to the protocol, snap frozen 
on liquid nitrogen and stored at − 80 °C prior to extraction. Frozen cells were 
thawed on ice and resuspended gently 1 ml hypotonic buffer (10 mM HEPES pH 
7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM PMSF, 0.5 mM DTT) and incubated for 
30 min on ice, then homogenized using a Dounce 40 times with a tight pestle, after 
which an aliquot was set aside as whole-cell extract. Cells were spun at 1,500 g for 
5 min and the supernatant removed. Next, 400 μ l of Buffer III.A (10 mM Tris pH 
7.4, 2 mM MgCl2, 1 mM PMSF, 5 mM CaCl2) was added gently with a wide-orifice 
p1000 tip and 1 μ l MNase (New England Biolabs, 2,000 U) was added. Nuclei were 
incubated for 30 min at 37 °C in a water bath, mixing every 10 min. To stop MNase 
digestion, 25 μ l of ice-cold 0.1 M EGTA was added to nuclei and an aliquot was set 
aside as the nuclei fraction. Nuclei were then centrifuged at 400 g for 10 min at 4 °C 
and the supernatant was kept as the MNase fraction. Nuclei were then washed with 
400 μ l Buffer III.B (same as Buffer III.A, but without CaCl2). Chromatin fractions 
were isolated by adding 400 μ l of IV.80, incubating for 30 min and spinning as 
above. The supernatant following each spin was saved, and the next salt buffer 
was added (IV.80, IV.150, IV.300, IV.600, 10 mM Tris pH 7.4, 2 mM MgCl2, 2 mM 
EGTA, 0.1% Triton X-100, with the amount of NaCl added (mM) denoted in the 
buffer name). All samples were prepared for western blot by boiling in 1× Laemmli 
buffer containing 0.1 M DTT.
Immunofluorescence. RWPE1;LACZ and RWPE1;SCHLAP1 cells were grown 
on 0.1% gelatin-coated glass coverslips, fixed in 2% paraformaldehyde, blocked in 
antibody dilution buffer (goat serum PBS), and immunostained for SMARCA4 
(abcam, 1:500 dilution) and SMARCB1 (abcam, 1:400 dilution) overnight at 4 °C 
in antibody dilution buffer. Coverslips were washed three times for 5 min in PBS 
and then stained in secondary antibody (goat anti-rabbit, Alexa Fluor 568, 1:500 
in antibody dilution buffer) for 45 min at 20–25 °C. Coverslips were again washed 
three times for min in PBS and mounted with Prolong Gold containing DAPI and 
imaged on a Zeiss Axio Imager 2.
Growth assays. Two-dimensional (2D) growth assays were performed by plating 
1,000 cells per well in 96-well plates. Assays were carried out 1, 3, and 5 days post 
plating using Cell Titer Glo (Promega). Three-dimensional (3D) growth assays 
were performed by plating 10 or 100 cells per well in 96-well plates and counting 
cell growth using Cell Titer Glo 3D (Promega) 4 days after plating.
Immunoprecipitation. Nuclear lysates and co-immunoprecipitation were 
performed as described previously4. Cells were washed with PBS and then 
centrifuged at 1,300 rpm for 10 min at 4 °C. Cells were washed with 20 packed 
cell volumes of hypotonic cell lysis buffer (10 mM HEPES–KOH pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM DTT plus protease inhibitors) and placed on ice for 
10 min to swell. Cells were then centrifuged at 1,300 rpm for 10 min at 4 °C. Cells 
were homogenized using a Dounce with a ‘B’ pestle in 2 packed cell volumes of 
hypotonic cell lysis buffer. Nuclei were pelleted at 1,300 rpm for 10 min at 4 °C, 
washed with 10 packed cell volumes of hypotonic cell lysis buffer, and centrifuged 
at 5,000 rpm for 10 min. Extractions were performed twice with 0.6 volume 
nuclear lysis buffer (20 mM HEPES–KOH pH 7.9, 25% glycerol, 420 mM KCl, 
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, and protease inhibitors). Lysates 
were clarified at 14,000 rpm for 10 min at 4 °C between extractions. Lysates were 
approximate nucleosome size of 150 bp. Tracks can be visualized using IGV28,  
and bigwig files are available under GEO accession number GSE114392.
Peak calling. Peaks were called using Macs2 (version 2.1.0 (ref. 29)) using the 
narrowpeak mode and the following parameters: Qval = 0.05 –keep-dup-all --fix-
bimodal –nomodel –extsize 150. In addition, we filtered the peaks against the 
ENCODE blacklist regions. Peaks were then annotated for the nearest transcription 
start site using ChIPPeakAnno30 relative to GENCODE v26.
ATAC-seq. ATAC-seq was performed as described previously10 but with 
modifications. In brief, 50,000 cells were collected and lysed in a buffer containing 
0.05% IGEPAL CA-630 before transposition with a Nextera library prep kit 
containing TN5 transposomes. Libraries were amplified using 6–8 PCR cycles 
to enrich for TN5 products and add indexes and sequenced as paired-end 50-bp 
libraries on a HiSeq 2500. ATAC-seq data are available under GEO accession 
number GSE114391.
ATAC-seq analysis. Nextera adapter sequences were trimmed using trim_galore 
and reads were aligned to hg38 using bowtie2 with the -X 2000 setting25. We 
removed any reads mapping to the mitochondrial genome and filtered any reads 
with a mapping quality less than 20 using SAMtools26. Peaks were called using 
Macs2 (version 2.1.0 (ref. 29)) using the narrowpeak mode using default settings and 
--keep-dup-all. Differential openness was identified use csaw31 with window size 
150 and background window size 5,000, and an adjusted false discovery rate (FDR) 
of 0.05 for the combined windows. Motif analysis was performed using HOMER by 
comparing the open or closed ATAC sites to the background set of static sites32.
Code availability. All commands, settings, or programs used to generate figures 
are described in the analysis section above. Any additional code used to generate 
figures is available upon reasonable request.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All data are available from GEO under accession number GSE114394. ATAC-seq 
and ChIP–seq read depth information can be found in Supplementary Table 7.
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diluted with storage buffer (20 mM HEPES–KOH pH 7.9, 20% glycerol, 0.2 mM 
EDTA, 0.2 mM DTT) to bring the final KCl concentration to 150 mM, and stored 
at − 80 °C.
Prior to beginning the immunoprecipitation, we washed protein A magnetic 
beads three times with PBS + 0.5% BSA at 4 °C. We resuspended beads in 400 μ l  
of 1× + 0.5% BSA, then added 4–10 μ g of antibody and incubated overnight at 
4 °C. The following day, we thawed the nuclear lysates on ice. Lysates were added 
to antibody-conjugated beads and incubated overnight. Beads were washed four 
times with BC-150 (20 mM HEPES–KOH pH 7.9, 0.15 M KCL, 10% glycerol, 
0.2 mM EDTA pH 8.0, 0.1% Tween-20, 0.5 mM DTT and protease inhibitors), 
two times with BC-100 (20 mM HEPES–KOH pH 7.9, 0.1 M KCL, 10% glycerol, 
0.2 mM EDTA pH 8.0, 0.1% Tween-20, 0.5 mM DTT and protease inhibitors), and 
once with BC-60 (20 mM HEPES–KOH, pH 7.9, 60 mM KCl, 10% glycerol, 0.5 mM 
DTT and protease inhibitors). Proteins were eluted from beads using 2× Laemmli 
buffer with 100 mM DTT for 10 min at 95 °C.
ChIP–seq. ChIP experiments were performed as described previously4. Cells were 
fixed for 30 min at 4 °C in 0.3% methanol-free formaldehyde, quenched for 5 min 
with 125 mM glycine, washed three times, and snap frozen in liquid nitrogen and 
stored at − 80 °C. Frozen pellets were thawed for 30 min on ice, resuspended each 
pellet in 1 ml swelling buffer (25 mM HEPES, 1.5 mM MgCl2, 10 mM KCl,  0.1% 
IGEPAL CA-630 containing 1 mM PMSF and 1× protease inhibitor cocktail, 
Roche) and incubated 10 min at 4 °C. Cells were dounced 20 strokes with a ‘B’ 
pestle, and then nuclei were pelleted at 2,000 rpm for 7 min at 4 °C. The nuclei 
were washed with 10 ml MNase digestion buffer (15 mM HEPES pH 7.9, 60 mM 
KCl, 15 mM NaCl, 0.32 M sucrose) and pelleted at 2,000 rpm for 7 min at 4 °C. 
The pellet was then resuspended in 1 ml MNase digestion buffer per 4 × 107 
cells,  3.3 μ l 1 M CaCl2 per ml,  PMSF (1 mM) and protease inhibitor cocktail (1× 
, Roche) and then incubated for 5 min at 37 °C to warm. We added MNase (New 
England Biolabs M0247S 2,000 U μ l−1) at 0.5 μ l per 1 × 107 cells and incubated for 
15 min at 37 °C with agitation. Following digestion, the MNase was chelated using 
1/50 volume 0.5 M EGTA on ice for 5 min. We added 1 volume of 2× IP buffer 
(20 mM TrisCl pH 8, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA), then passed 
the sample through a 21-gauge needle five times and added Triton X-100 to 1% 
final concentration. The sample was cleared at 13,000 rpm for 15 min at 4 °C, and 
chromatin was incubated with antibody overnight at 4 °C (SMARCA4 (Abcam 
ab110641), SMARCA2 (Cell signaling 11966), SMARCB1 (Abcam)). Antibody–
chromatin complexes were captured with protein A magnetic beads (Bio-Rad) 
for 2 h at 4 °C and washed five times with Agilent RIPA (50 mM HEPES pH 7.9, 
500 mM LiCl, 1 mM EDTA, 1% IGEPAL CA-630, 0.7% Na-deoxycholate) and 
once with 10 mM Tris, 1 mM EDTA, 50 mM NaCl. DNA was eluted at 65 °C with 
agitation using 100 μ l freshly made 1% SDS,  100 mM NaHCO3. Crosslinks were 
reversed overnight by adding 5 μ l of 5 M NaCl and incubating at 65 °C. DNA was 
treated with 3 μ l RNaseA for 30 min at 37 °C and then proteinase K for 1 h at 56 °C 
and purified with Zymo Clean and Concentrator ChIP Kit and quantified using 
qubit before library preparation (Kapa Hyperprep).
ChIP–seq analysis. Reads were aligned to hg38 using bowtie2 (ref. 25) using 
the sensitive parameters, and duplicates were removed using SAMtools26. For 
visualization, bigwig tracks were generated using DeepTools27 (version 2.5.2), 
bamCoverage tool with a binsize of 30 bp and extending fragments to the 
